Postexposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault

被引:63
|
作者
Bamberger, JD
Waldo, CR
Gerberding, JL
Katz, MH
机构
[1] Univ Calif San Francisco, San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA
[2] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[4] Univ Calif San Francisco, Ctr Aids Prevent Studies, San Francisco, CA 94143 USA
[5] Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA USA
来源
AMERICAN JOURNAL OF MEDICINE | 1999年 / 106卷 / 03期
关键词
D O I
10.1016/S0002-9343(99)00018-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although the 1998 Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases recommend offering postexposure prophylaxis for human immunodeficiency virus (HN) infection following sexual assault, there are no detailed protocols on how to provide this treatment. Postexposure prophylaxis has been shown to lower the risk of seroconversion following occupational exposure to HIV by 81%, but has not yet been evaluated following sexual exposure. Though scientific data are limited, victims of sexual assault should be given the best information available to make an informed decision regarding postexposure prophylaxis. When the choice is made to take medications to prevent HIV infection, treatment should be initiated as soon as possible, but no later than 72 hours following the assault, and should be continued for 28 days. HIV postexposure prophylaxis should be provided in the context of a comprehensive treatment and counseling program that recognizes the physical and psychosocial trauma experienced by victims of sexual assault. (C) 1999 by Excerpta Medica, Inc.
引用
收藏
页码:323 / 326
页数:4
相关论文
共 50 条
  • [31] HIV prophylaxis following sexual assault: Experience with 30 survivors
    Klemens, S
    Avery, L
    Weaver, G
    Wong, C
    Sable, N
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1214 - 1214
  • [32] Human Immunodeficiency Virus Postexposure Prophylaxis for Medical Trainees on International Rotations
    Mohan, Shaulnie
    Sarfaty, Suzanne
    Hamer, Davidson H.
    JOURNAL OF TRAVEL MEDICINE, 2010, 17 (04) : 264 - 268
  • [33] Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers
    Scheid, DC
    Hamm, RM
    Stevens, KW
    PHARMACOECONOMICS, 2000, 18 (04) : 355 - 368
  • [34] Postexposure prophylaxis following HIV exposure
    Barry, MA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (14): : 1269 - 1269
  • [35] Cost Effectiveness of Human Immunodeficiency Virus Postexposure Prophylaxis for Healthcare Workers
    Dewey C. Scheid
    Robert M. Hamm
    Kevin W. Stevens
    PharmacoEconomics, 2000, 18 : 355 - 368
  • [36] Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus
    Havens, PL
    PEDIATRICS, 2003, 111 (06) : 1475 - 1489
  • [37] Postexposure prophylaxis against hepatitis B, hepatitis C and human immunodeficiency virus infection in healthcare workers
    Vasic, Bojan
    Andjelic, Spaso
    Lukic, Relja
    Jevtovic, Djordje
    Grbovic, Leposava
    Vasiljevic, Tatjana
    Dragovic, Gordana
    VOJNOSANITETSKI PREGLED, 2011, 68 (11) : 975 - 978
  • [38] Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection
    Nerad, JL
    Kessler, HA
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (11) : 1635 - 1636
  • [39] Postexposure prophylaxis after sexual exposure to HIV
    Roland, Michelle E.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2007, 20 (01) : 39 - 46
  • [40] Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus
    Pinkerton, SD
    Martin, JN
    Roland, ME
    Katz, MH
    Coates, TJ
    Kahn, JO
    ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (01) : 46 - 54